Need professional-grade analysis? Visit stockanalysis.com
$481.97M
N/A
N/A
N/A
ProKidney Corp. (PROK) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $2.09, down 4.13% from the previous close.
Over the past year, PROK has traded between a low of $0.56 and a high of $5.18. The stock has gained 129.6% over this period. It is currently 59.7% below its 52-week high.
ProKidney Corp. has a market capitalization of $481.97M.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Side-by-side comparison against top Healthcare peers.